Alzheimer’s: A Progressive Brain Disease: Causes, Symptoms, and Prevention

  • Fakhra Amin
  • Anas Shamsi
  • Muhammad Nadeem Asghar
  • Peerzada Shariq Shaheen Khaki
  • Mohd Shahnawaz Khan
  • Shams Tabrez
  • Syed Kashif Zaidi
  • Wajihullah Khan
  • Bilqees Bano


Alzheimer’s disease (AD) is an irretrievable, mysterious, and devastating neurodegenerative disorder that leads to memory loss and impaired cognitive function. Specifically, AD patients suffer from poor thinking skills and lack potential to perform simple activities. Dementia is multifactorial disorder and considered as the main cause of AD. Alzheimer’s disease is characterized by the presence of large quantities of two remarkable structures, i.e., amyloid plaques and neurofibrillary tangles which are the hallmarks of AD. Both of these structures are misfolded proteins and thought to play an important role in the degeneracy of neurons, ultimately leading to most of AD symptoms. Another common feature of AD is the wrecking of intracellular connections which results in reduced cell function and cell death. Neurofibrillary tangles are twisted fibers which are found inside the neurons and are produced by hyperphosphorylation of a microtubule-associated protein, i.e., tau. Smoking and obesity are the putative risk factors for dementia and cardiovascular disease. Deficiency of vitamins, especially thiamine (B1), riboflavin (B2), niacin (B3), pyridoxine (B6), folate (B9), and cobalamin (B12), is associated with cognitive dysfunction and AD. Type-2 diabetes (T2D) and prediabetic insulin resistance have also been suggested as the risk factors for cerebrovascular injury and cognitive decline, eventually leading to dementia. Cognitive impairment in T2D is caused by deposits of amylin, an amyloidogenic hormone synthesized and cosecreted with insulin by pancreatic β-cells. The menace of AD can be lowered down by certain anti-inflammatory drugs, proper intake of vitamin B, nurturing physical and leisure activities. In addition, AD can also be controlled by decreasing the candidate risk factors for cardiovascular disease. Anti-amyloid approaches such as vaccination may provide a promising tool to establish safer therapeutic approaches.


Alzheimer’s Dementia Amyloid plague Tau proteins Neurofibrillary tangles 



We greatly acknowledge facility provided by Aligarh Muslim University, Aligarh, India; University of Quebec, Trois-Rivieres, Canada; King Fahd Medical Research Center (KFMRC), Jeddah; King Abdulaziz University, Jeddah; and King Saud University, Riyadh, Saudi Arabia for carrying out this work.


  1. Aliev G, Obrenovich ME, Tabrez S, Jabir NR, Reddy P, Li Y, Burnstock G, Cacabelos R, Kamal MA (2013) Link between cancer and Alzheimer disease via oxidative stress induced by nitric oxide-dependent mitochondrial DNA over-proliferation and deletion. Oxidative Med Cell Longev 2013:962984CrossRefGoogle Scholar
  2. Alzheimer Society of Canada (2012) Stages of Alzheimer’s disease (what happens). Toronto.
  3. Alzheimer’s Association (2004) All rights reserved. Stages of Alzheimer’s Disease Fact SheetGoogle Scholar
  4. Alzheimer’s Association © (2007) All rights reserved. 1.800.272.3900|
  5. Alzheimer’s Association (2015) Alzheimer’s disease facts and figures. Alzheimers Dement 11(3):332CrossRefGoogle Scholar
  6. ALZHEIMER’S DISEASE Unraveling the Mystery, U.S. Department of Health and Human Services NIH Publication Number: 08–3782 September 2008Google Scholar
  7. Alzheimer’s Disease Education & Referral (ADEAR) Center (2012) A Service of the National Institute on aging, National Institutes of Health, U.S. Department of Health and Human Services. NIH Publication No. 11-6423Google Scholar
  8. Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166(4):367–378PubMedCrossRefPubMedCentralGoogle Scholar
  9. Anstey KJ, Cherbuin N, Budge M, Young J (2011) Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 12(5):e426–e437. ReviewPubMedCrossRefPubMedCentralGoogle Scholar
  10. Araki Y, Nomura M, Tanaka H et al (1994) MRI of the brain in diabetes mellitus. Neuroradiology 36:101–103PubMedCrossRefPubMedCentralGoogle Scholar
  11. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661–666PubMedCrossRefPubMedCentralGoogle Scholar
  12. Ashraf GM, Tabrez S, Jabir NR, Firoz CK, Ahmad S, Hassan I, Alexiou A, Kamal MA (2015) An overview on global trends in nano-technological approaches for Alzheimer therapy. Curr Drug Metab 16(8):719–727PubMedCrossRefPubMedCentralGoogle Scholar
  13. Ashraf GM, Chibber S, Mohammad ZSK, Tabrez S, Ahmad A, Shakil S, Mustaq G, Baeesa S, Kamal MA (2016) Recent updates on the association between Alzheimer disease and vascular dementia. Med Chem 12(3):226–237PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23(4):213–227PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bell ET (1959) Hyalinization of the islets of Langerhans in nondiabetic individuals. Am J Pathol 35(4):801–805PubMedPubMedCentralGoogle Scholar
  16. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee DE (1997) Homocysteine, atherosclerosis and prevalence cardiovascular disease in the elderly: the Rotterdam study. J Intern Med 242:339–347PubMedCrossRefPubMedCentralGoogle Scholar
  17. Brayne C, Gill C, Huppert FA et al (1998) Vascular risks and incident dementia: results from a cohort study of the very old. Dement Geriatr Cogn Disord 9PubMedCrossRefPubMedCentralGoogle Scholar
  18. Byrd C, RN, MSN, ANP, ACNP, CNRN (2006) Normal Pressure Hydrocephalus DEMENTIA’S CAUSE. Nurse Pract 31(7):28–29PubMedCrossRefPubMedCentralGoogle Scholar
  19. Cholerton B, Gleason CE, Baker LD, Asthana S (2002) Estrogen and Alzheimer’s disease: the story so far. Drugs Aging 19:405–427PubMedCrossRefPubMedCentralGoogle Scholar
  20. Craft S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66(3):300–305PubMedPubMedCentralCrossRefGoogle Scholar
  21. Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C et al (2011) Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77:461–468PubMedPubMedCentralCrossRefGoogle Scholar
  22. den Heijer T, Vermeer SE, van Dijk EJ et al (2003) Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46:1604–1610CrossRefGoogle Scholar
  23. Devanand DP, Sano M, Tang MX, Taylor S, Gurland BJ, Wilder D et al (1996) Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry 53:175–182PubMedCrossRefPubMedCentralGoogle Scholar
  24. Elias PK, Elias MF, D’Agostino RB et al (1997) NIDDM and blood pressure as risk factors for poor cognitive performance: the Framingham study. Diabetes Care 20:1388–1395PubMedCrossRefPubMedCentralGoogle Scholar
  25. Elias MF, Elias PK, Sullivan LM, Wolf PA, D’Agostino RB (2005) Obesity, diabetes and cognitive deficit: the Framingham heart study. Neurobiol Aging 26(Suppl 1):11–16PubMedCrossRefPubMedCentralGoogle Scholar
  26. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A (2001) Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the epidemiology of vascular aging study. Diabetes Care 24:366–370PubMedCrossRefPubMedCentralGoogle Scholar
  27. Goldman JS, Hahn SE, Bird T (2011) Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 13:597–605PubMedPubMedCentralCrossRefGoogle Scholar
  28. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 287:329–336PubMedCrossRefPubMedCentralGoogle Scholar
  29. Gregg EW, Yaffe K, Cauley JA et al (2000) Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of osteoporotic fractures research group. Arch Intern Med 160:174–180PubMedCrossRefPubMedCentralGoogle Scholar
  30. Greig NH, Kamal MA, Jabir NR, Tabrez S, Nasim FH, Abuzenadah AM, Aliev G (2013) Specific cholinesterase inhibitors: A potential tool to assist in management of Alzheimer disease. Front Drug Des Discovery 6:366–386Google Scholar
  31. Gudala K, Bansal D, Schifano F, Bhansali A (2013) Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. Diabetes Investig 4(6):640–650CrossRefGoogle Scholar
  32. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H et al (2000) Head injury and the risk of AD in the MIRAGE study. Neurology 54:1316–1323PubMedCrossRefPubMedCentralGoogle Scholar
  33. Haan MN, Mungas DM, Gonzalez HM, Ortiz TA, Acharya A, Jagust WJ (2003) Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc 51:169–177PubMedCrossRefPubMedCentralGoogle Scholar
  34. Hakim S, Adams RD (1965) The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. J Neurol Sci 2:307–327PubMedCrossRefPubMedCentralGoogle Scholar
  35. Harrington M, Weuve J, Jackson JW, Blacker D (2014) Physical activity. The AlzRisk Database. Alzheimer Research Forum. Available at:
  36. Hassing LB, Johansson B, Nilsson SE et al (2002) Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 14:239–248PubMedCrossRefPubMedCentralGoogle Scholar
  37. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al (2000) Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 54:295–301PubMedCrossRefPubMedCentralGoogle Scholar
  38. Herrmann W, Obeid R (2007) Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid. Clin Chem Lab Med 45(12):1614–1620, ISSN 1434-6621PubMedPubMedCentralGoogle Scholar
  39. Hickey J (2003) The Clinical Practice of Neurological and Neurosurgical Nursing, 5th edn. Williams & Wilkins, PhiladelphiaGoogle Scholar
  40. Höppener JWM, Ahren B, Lips CJM (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6):411–419PubMedCrossRefPubMedCentralGoogle Scholar
  41. Igor OK (2014) Review article, Alzheimer’s disease: a clinical and basic science review. MSRJ 4:24Google Scholar
  42. Int’ Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001) Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345:1515–1521CrossRefGoogle Scholar
  43. Islam B, Tabrez S (2017) Management of Alzheimer’s disease- an insight of the enzymatic and other novel potential targets. Int J Biol Macromol 97:700–709PubMedCrossRefPubMedCentralGoogle Scholar
  44. Islam B, Khan MS, Jabir NR, Kamal MA, Tabrez S (2017a) Elucidating treatment of Alzheimer’s disease via different receptors. Curr Top Med Chem 17(12):1400–1407CrossRefGoogle Scholar
  45. Islam B, Zaidi SK, Kamal MA, Tabrez S (2017b) Exploration of various proteins for the treatment of Alzheimer’s disease. Curr Drug Metab 18(9):808–813PubMedCrossRefPubMedCentralGoogle Scholar
  46. Jabir NR, Kamal MA, Abuzenadah AM, Gan SH, Alama MN, Baeesa SS, Tabrez S (2014) Alzheimer’s and type 2 diabetes treatment via common enzyme targeting. CNS Neurol Disord Drug Targets 13:299–304PubMedCrossRefPubMedCentralGoogle Scholar
  47. Jabir NR, Firoz CK, Baeesa SS, Ashraf GM, Kamal MA, Tabrez S (2015) Synopsis on the linkage of Alzheimer’s and Parkinson’s disease with Chronic diseases. CNS Neurosci Ther 21(1):1–7PubMedCrossRefPubMedCentralGoogle Scholar
  48. Jabir NR, Khan FR, Tabrez S∗. (2018) Cholinesterase targeting by polyphenols: a therapeutic approach for the treatment of Alzheimer’s disease. CNS Neurosci Ther 24:753–762PubMedPubMedCentralCrossRefGoogle Scholar
  49. Jorm AF (2002) Prospects for the prevention of dementia. Aust J Ageing 21:9–13CrossRefGoogle Scholar
  50. Jorm AF, van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A et al (1991) Psychiatric history and related exposures as risk factors for Alzheimer’s disease: a collaborative re-analysis of case control studies. Int J Epidemiol 20(suppl. 2):S43–S47PubMedCrossRefPubMedCentralGoogle Scholar
  51. Jurgens CA, Toukatly MN, Fligner CL, Udayasankar J, Subramanian SL, Zraika S, Aston-Mourney K, Carr DB, Westermark P, Westermark GT, Kahn SE, Hull RL (2011) β-cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178(6):2632–2640PubMedPubMedCentralCrossRefGoogle Scholar
  52. Kahn SE, D’Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, Porte D Jr (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39(5):634–638PubMedCrossRefPubMedCentralGoogle Scholar
  53. Kamal MA, Priyamvada S, Arivarasu NA, Jabir NR, Tabrez S, Greig NH (2014) Linking Alzheimer’s disease and type 2 diabetes mellitus via aberrant insulin signalling and inflammation. CNS Neurol Disord Drug Targets 13:338–346PubMedPubMedCentralCrossRefGoogle Scholar
  54. Knopman D, Boland LL, Mosley T et al (2001) Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56:42–48PubMedCrossRefPubMedCentralGoogle Scholar
  55. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ (1991) Clinical risk factors for Alzheimer’s disease: a population-based case-control study. Neurology 41:1393–1397PubMedCrossRefPubMedCentralGoogle Scholar
  56. Emel Koseoglu (2011). The relations between the vitamins and Alzheimer Dementia, Alzheimer’s disease pathogenesis-core concepts, shifting paradigms and therapeutic targets, Dr. Suzanne De La Monte (Ed.),Google Scholar
  57. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR et al (2000) Midlife blood pressure and dementia: the Honolulu- Asia aging study. Neurobiol Aging 21(1):49–55PubMedCrossRefPubMedCentralGoogle Scholar
  58. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J et al (1996) Risk of dementia among relatives of Alzheimer’s disease patients in the MIRAGE study: what is in store for the oldest old? Neurology 46(3):641–650PubMedCrossRefPubMedCentralGoogle Scholar
  59. Leibson CL, Rocca WA, Hanson VA et al (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145:301–308PubMedCrossRefPubMedCentralGoogle Scholar
  60. Leighton B, Cooper GJS (1988) Pancreatic amylin and calcitonin gene-related peptide causes resistance to insulin in skeletal muscle in vitro. Nature 355(6191):632–635CrossRefGoogle Scholar
  61. Loef M, Walach H (2013) Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. Obesity (Silver Spring) 21(1):E51–E55CrossRefGoogle Scholar
  62. Logroscino G, Kang JH, Grodstein F (2004) Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 328:548PubMedPubMedCentralCrossRefGoogle Scholar
  63. Loy CT, Schofield PR, Turner AM, Kwok JBJ (2014) Genetics of dementia. Lancet 383:828–840PubMedCrossRefPubMedCentralGoogle Scholar
  64. Luchsinger JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 30(2):S185–S198PubMedPubMedCentralCrossRefGoogle Scholar
  65. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R (2001) Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154:635–641PubMedCrossRefPubMedCentralGoogle Scholar
  66. MacKnight C, Rockwood K, Awalt E, McDowell I (2002) Diabetes mellitus and the risk of dementia, Alzheimer’s disease and vascular cognitive impairment in the Canadian study of health and aging. Dement Geriatr Cogn Disord 14:77–83PubMedCrossRefPubMedCentralGoogle Scholar
  67. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer’s disease? Eur J Neurol 9:377–382PubMedCrossRefPubMedCentralGoogle Scholar
  68. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer’s and other neurodegenerative diseases. Brain Res Rev 21:195–218PubMedCrossRefPubMedCentralGoogle Scholar
  69. Meng XF, Yu JT, Wang HF, Tan MS, Wang C, Tan CC, Tan L (2014) Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis 42(4):1295–1310PubMedCrossRefPubMedCentralGoogle Scholar
  70. Micheau J, Durkin TP, Destrade C, Rolland Y, Jaffard R (1985) Chronic administration of sulbutiamine improves long term memory formation in mice: possible cholinergic mediation. Pharmacol Biochem Behav 23(2):195–198, ISSN 0091-3057PubMedCrossRefPubMedCentralGoogle Scholar
  71. Molina JM, Cooper GJS, Leighton B, Olefsky JM (1990) Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 39(2):260–265PubMedCrossRefPubMedCentralGoogle Scholar
  72. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N et al (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer’s disease in a bi-racial community study. JAMA 287:3230–3237PubMedCrossRefPubMedCentralGoogle Scholar
  73. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 283:1007–1015PubMedCrossRefPubMedCentralGoogle Scholar
  74. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, Keller JN, Jicha GA, Davis D, Wang-Xia W, Hartman A, Katz DG, Markesbery WR (2009) Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 1792(5):454–469PubMedCrossRefPubMedCentralGoogle Scholar
  75. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J et al (2011) Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension 58(1):22–28PubMedCrossRefPubMedCentralGoogle Scholar
  76. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53(9):1937–1942PubMedCrossRefPubMedCentralGoogle Scholar
  77. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 51:1256–1262PubMedCrossRefPubMedCentralGoogle Scholar
  78. Pendlebury ST, Rothwell PM (2009) Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 8(11):1006–1018PubMedCrossRefPubMedCentralGoogle Scholar
  79. Nowotny Petra, Washington University School of Medicine, Saint Louis, Missouri, USA, Jennifer M Kwon, Washington University School of Medicine, Saint Louis, Missouri, USA Alison M Goate, ENCYCLOPEDIA OF LIFE SCIENCES/ & 2001 Nature Publishing Group/
  80. Prof. Colin Masters, Professor of Pathology, University of Melbourne, personal communication, April 2002Google Scholar
  81. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3):137–152PubMedPubMedCentralCrossRefGoogle Scholar
  82. Riedel WJ, Jorissen B, Nutrients L (1998) Age and cognitive function. Curr Opin Clin Nutr Metab Care 1(6):579–585, ISSN 163-1950PubMedCrossRefPubMedCentralGoogle Scholar
  83. Rifat SL, Eastwood MR, McLachlan DRC, Corey PN (1990) Effect of exposure of miners to aluminium powder. Lancet 336:1162–1165PubMedCrossRefPubMedCentralGoogle Scholar
  84. Ritchie K, Touchon J (2000) Mild cognitive impairment: conceptual basis and current nosological status. Lancet 355:225–228PubMedCrossRefPubMedCentralGoogle Scholar
  85. Rönnemaa E, Zethelius B, Lannfelt L, Kilander L (2011) Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord 31(6):460–466PubMedCrossRefPubMedCentralGoogle Scholar
  86. Rusanen M, Kivipelto M, Quesenberry CP, Zhou J, Whitmer RA (2011) Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 171(4):333–339PubMedCrossRefPubMedCentralGoogle Scholar
  87. Sajeev G, Weuve J, McQueen MB, Blacker D (2014) Diabetes. The AlzRisk Database Alzheimer Research Forum Available at:
  88. Schmidt R, Launer LJ, Nilsson LG et al (2004) Magnetic resonance imaging of the brain in diabetes: the cardiovascular determinants of dementia (CASCADE) study. Diabetes 53:687–692PubMedCrossRefPubMedCentralGoogle Scholar
  89. Schnaider Beeri M, Goldbourt U, Silverman JM et al (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 63:1902–1907CrossRefGoogle Scholar
  90. Skoog I (1994) Risk factors for vascular dementia: a review. Dementia 5:137–144PubMedPubMedCentralGoogle Scholar
  91. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L et al (1996) 15-year longitudinal study of blood pressure and dementia. Lancet 347:1141–1145PubMedCrossRefPubMedCentralGoogle Scholar
  92. Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement and Geriatr Disord 28:75–80CrossRefGoogle Scholar
  93. Speck CE, Kukull WA, Brenner DE, Bowen JD, McCormick WC, Teri L et al (1995) History of depression as a risk factor for Alzheimer’s disease. Epidemiology 6:366–369PubMedCrossRefPubMedCentralGoogle Scholar
  94. Srodulski S, Sharma S, Bachstetter AB, Brelsfoard JM, Pascual C, Xie XS, Saatman KE, Van Eldik LJ, Despa F (2014) Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener 9:30. PubMed PMID: 25149184; PubMed CentralCrossRefPubMedPubMedCentralGoogle Scholar
  95. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC (1997) A twin study of late-onset depression and apolipoprotein E e4 as risk factors for Alzheimer’s disease. Biol Psychiatry 41:851–856PubMedCrossRefPubMedCentralGoogle Scholar
  96. Storey E, Masters C (1995) Amyloid, aluminium and the aetiology of Alzheimer’s disease. MJA 163:256–259PubMedPubMedCentralGoogle Scholar
  97. THE DEMENTIAS, Hope through research, National Institute of Neurological Disorders and Stroke National Institute on Aging, NIH publication no: 132252, 2013Google Scholar
  98. U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Aging, NIH Publication No. 11 5441 June 2011Google Scholar
  99. Vagelatos NT, Eslick GD (2013) Type 2 diabetes as a risk factor for Alzheimer’s disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 35(1):152–160PubMedCrossRefPubMedCentralGoogle Scholar
  100. Verrees M, Selman W (2004) Management of normal pressure hydrocephalus. Am Fam Phyikian 70:1071–1078Google Scholar
  101. Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77(2):91–94PubMedCrossRefPubMedCentralGoogle Scholar
  102. Westermark P, Andersson A, Westermark GT (2011) Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91(3):795–826PubMedCrossRefPubMedCentralGoogle Scholar
  103. Willis BL, Gao A, Leonard D, DeFina LF, Berry JD (2012) Midlife fitness and the development of chronic conditions in later life. Arch Intern Med 172(17):1333–1340PubMedPubMedCentralCrossRefGoogle Scholar
  104. Wu W, Brickman AM, Luchsinger J, Ferrazzano P, Pichiule P, Yoshita M et al (2008) The brain in the age of old: the hippocampal formation is targeted differentially by diseases of late life. Ann Neurol 64:698–706PubMedPubMedCentralCrossRefGoogle Scholar
  105. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63:1181–1186PubMedCrossRefPubMedCentralGoogle Scholar
  106. Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658–663PubMedCrossRefPubMedCentralGoogle Scholar
  107. Yoshitake T, Kiyohara Y, Kato I et al (1995) Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama study. Neurology 45:1161–1168PubMedCrossRefPubMedCentralGoogle Scholar
  108. Zierath JR, Galuska D, Engstrom A, Johnson KH, Betsholtz C, Westermark P, Wallberg-Henriksson H (1992) Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in vitro incubated human muscle strips. Diabetologia 35(1):26–31PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Fakhra Amin
    • 1
  • Anas Shamsi
    • 2
  • Muhammad Nadeem Asghar
    • 3
  • Peerzada Shariq Shaheen Khaki
    • 2
  • Mohd Shahnawaz Khan
    • 4
  • Shams Tabrez
    • 5
    • 6
  • Syed Kashif Zaidi
    • 7
  • Wajihullah Khan
    • 1
  • Bilqees Bano
    • 2
  1. 1.Department of Zoology, Faculty of Life SciencesAligarh Muslim UniversityAligarhIndia
  2. 2.Department of Biochemistry, Faculty of Life SciencesAligarh Muslim UniversityAligarhIndia
  3. 3.Department of Medical BiologyUniversity of QuebecTrois RiveresCanada
  4. 4.Protein Research Chair, Department of Biochemistry, College of SciencesKing Saud UniversityRiyadhSaudi Arabia
  5. 5.King Fahd Medical Research CenterKing Abdulaziz UniversityJeddahSaudi Arabia
  6. 6.Department of Medical Laboratory Technology, Faculty of Applied Medical SciencesKing Abdulaziz UniversityJeddahSaudi Arabia
  7. 7.Center of Excellence in Genomic Medicine ResearchKing Abdulaziz UniversityJeddahSaudi Arabia

Personalised recommendations